Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Pityriasis Rubra Pilaris
NCT06444399Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deucravacitinib in pityriasis rubra pilaris (PRP), sponsored by Mayo Clinic. Primary endpoint: Psoriasis Area and Severity Index at 24 weeks. Started Jul 2024; status: completed.
02
Drugs
deucravacitinib
03
Conditions
pityriasis rubra pilaris (PRP)
Beyond the preview
Go deeper on NCT06444399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444399.